Clinical Trial Update: Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan [Phase 4]

View source ↗

Summary

Phase 4 trial assessing safety of lixisenatide added to sulfonylurea and basal insulin in type 2 diabetes patients who fast during Ramadan.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Basal insulin (basal insulin)
• Lyxumia (lixisenatide)
• Sulfonylurea (sulfonylurea)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED